GLP1R and type 2 diabetes mellitus: Osaka et al. demonstrated that treatment with semaglutide leads to favorable changes in appendicular skeletal muscle mass among older adults with T2DM and HF, signifying potential for GLP-1 RAs to address sarcopenia [65].